Ocugen, Inc. (OCGN) stock
Close on Nov 11, 2026Market cap $325.68MP/E –Yield –
Ocugen, Inc. grew revenue 8.8% to $4.41M over fiscal 2025. Free cash flow was -$63.90M. At the latest close the market valued the company at $325.68M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $325.68M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -19.62%
Fundamentals
- Revenue
- $4.41M
- Net income
- -$65.36M
- Free cash flow
- -$63.90M
- Book value per share
- -$0.05
- Diluted shares
- 339M
Trading
- Next earnings
- Mar 3, 2027 (estimated, during market hours)
- Previous close
- $0.95
- Open
- $1.01
- Day's range
- $0.91 – $1.01
- Volume
- 5,048,138
- Average volume (20 days)
- 6,743,176
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.68
- 52-week range
- $0.69 – $2.73
- RSI (14 days)
- 57.8
- Volatility (1 year)
- 81.9%
- Relative volume
- 0.81×
- WACC
- 13.3%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | OCGN | S&P 500 | Difference | OCGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.5% | -2.4% | +2.9 pts | ||
| 3 months | -29.9% | -1.2% | −28.7 pts | ||
| Year to date | -28.9% | +12.3% | −41.2 pts | ||
| 1 year | -27.8% | +12.4% | −40.2 pts | ||
| 3 years | +166.9% | +78.8% | +88.0 pts | +38.7% | +21.4% |
| 5 years | -88.9% | +75.2% | −164.1 pts | -35.6% | +11.9% |
| 10 years | -99.2% | +311.1% | −410.3 pts | -38.6% | +15.2% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ocugen filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Update
- Update
About Ocugen
Biological Products, (No Diagnostic Substances)
Ocugen, Inc. is a late-stage biotechnology company that develops gene therapies, biologics, cell therapies, and vaccines to treat ocular diseases, joint conditions, and respiratory infections. Its primary pipeline features a modifier gene therapy platform with lead candidates OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy. The company also develops OCU200 for diabetic eye disorders, NeoCart for adult knee cartilage injuries through its subsidiary OrthoCellix, and inhaled mucosal vaccines targeting COVID-19 and influenza. Its products target individuals with rare inherited retinal disorders, degenerative blindness, cartilage damage, and infectious illnesses.
Company profile, executives and historyOcugen stock: common questions
What is Ocugen's stock price?
OCGN closed at $0.96 on Nov 11, 2026, up 1.09% on the day. Over the past 52 weeks it traded between $0.69 and $2.73.
What is Ocugen's market cap?
Ocugen was worth $325.68M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does Ocugen make?
Ocugen reported revenue of $4.41M for fiscal 2025, up 8.8% from a year earlier.
Does Ocugen pay a dividend?
No. Ocugen has not paid a cash dividend over the last twelve months.
When does Ocugen report earnings next?
Ocugen is expected to report Q4 FY2026 results on Mar 3, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has OCGN stock performed over the past year?
Including dividends, OCGN returned -27.8% over the past year, against +12.4% for the S&P 500.
How many OCGN shares are sold short?
108M shares were sold short at the latest FINRA report, 32.54% of the float, or 16.4 days of average trading volume.
Who are Ocugen's competitors?
Companies most similar to Ocugen by business, industry and size include PRME, FATE, LCTX, TSHA, CRIS.
See a number that looks wrong?